Moran Amit MD PhD; AACR 2026: Oral Intralesional PD 1 Blockade Promises Less Risk of Progression to Oral Cancer than Surgery, with Preserved Quality of Life

About this episode

Moran Amit MD PhD discusses the potential of intralesional PD 1 blockade to reduce the risk of progression to oral cancer compared to surgery while preserving quality of life.

Oral Intralesional PD 1 Blockade Promises Less Risk of Progression to Oral Cancer than Surgery, with Preserved Quality of Life An interview with: Moran Amit MD PhD, Head and Neck Surgeon, Assistant Professor, University of Texas MD Anderson Cancer Center, Houston, Texas USA. SAN DIEGO, USA—The risk that oral pre-cancerous lesions will progress to cancer may effectively be reduced by using intralesional injections of a checkpoint inhibitor, sparing the need for multiple surgical resections and the loss of oral function such surgery can bring. This hope was held out at the AACR 2026 Annual Meeting in San Diego by Moran Amit MD PhD, who is a head and neck surgeon and assistant professor, at the University of Texas MD Anderson Cancer Center in Houston, Texas. After reporting his new data to the conference he talked with our reporter, Peter Goodwin: IN: [GOODWIN] “I am at the American Association …. OUT: ……..the Audio Journal of Oncology, I’m Peter Goodwin 10:13 secs AACR 2006 ABSTRACT: CT188 Title: Intralesional PD1 blockade for Oral Cancer Prevention: First in Class Phase1 Trial Authors: Moran Amit, Robert Saddawi-Konefka, Shorook Naara, Fred Netto, Fred Netto, Chen F Fushun, Yen…

People in this episode

Host: Peter Goodwin

Guest: Moran Amit MD PhD

Topics covered

• oral cancer
• intralesional PD 1 blockade
• surgery alternatives
• quality of life
• AACR 2026

Keywords

• oral cancer
• PD 1 blockade
• intralesional injections
• surgery
• quality of life
• AACR 2026
• head and neck surgery

Mentioned in this episode

Organizations: University of Texas MD Anderson Cancer Center

Places: Houston, Texas USA

More episodes of Audio Journal of Oncology Podcast

• Jonathan Wesley Riess MD; 2026 AACR: Investigational KRAS(ON) Inhibitor Zoldonrasib Showed Effective and Durable Responses in Patients With Advanced G12D-mutated Lung Cancer · May 6, 2026 · 8 min
• Marija Balic MD PhD, AACR 2026: Whole Exome Sequencing of ctDNA Informs Post-Neoadjuvant Therapy Options for Patients with Triple Negative Early Breast Cancer · April 30, 2026 · 11 min
• Tao Zhu MD; AACR 2026: Anti-Claudin 6 Antibody Drug Conjugate Benefits Patients with Advanced Platinum-Resistant Ovarian Cancer with Low Toxicity · April 28, 2026 · 5 min
• Byoung Chul Cho MD PhD; AACR 2026: New Generation KRAS G12C Inhibitor Brings Promising Responses Even in Patients with Advanced Lung Cancers Refractory to Previous KRAS-targeted Therapy · April 24, 2026 · 8 min
• Elena Garralda MD PhD, AACR 2026: Molecular Glue Degrader Improves Outcomes in Heavily Pre-treated Patients with Advanced Solid Tumors · April 23, 2026 · 9 min
• Icro Meattini MD; 2026 EBCC: Safe to Avoid Endocrine Therapy in Older Women with Low Risk Breast Cancers: EUROPA Study Interim Findings · April 16, 2026 · 5 min